| | | | | | |
Biotech deals more than doubled in first half of 2013, report finds Biopharmaceutical firms struck 1,234 deals during the first half of 2013, up from 565 in the first half of the previous year. Licensing and joint ventures accounted for 30% of total transactions, according to a Recap report. The number of licensing and joint venture agreements increased 39% from the same period last year. Total deal value reached $73.3 billion, with $52.6 billion coming from mergers and acquisitions. BioWorld (free content) (8/7)  | Report Track & Traceability
Commerce in Motion and JDA, surveyed 130 quality control, supply chain and operations professionals. The goal was to understand their ability to effectively track, trace, and recall products. Per the study financial cost is the greatest risk associated with the inability to trace items. Download the free report now to see where the Life Sciences industry stands on traceability. |
 | Amgen raises bid for Onyx to $130 per share, source indicates Amgen reportedly increased its bid to acquire Onyx Pharmaceuticals from $120 to $130 per share. If successful, Amgen will get the rights to Onyx's blood cancer drug Kyprolis, which is expected to generate sales of $2.4 billion by 2019, according to estimates by analysts. Onyx and Amgen did not comment on the reported new bid. Bloomberg (8/6) | | Industrial & Environmental | Valero withdraws from cellulosic project in Mich. A cellulosic project in Kinross, Mich., planned by Mascoma and J.M. Longyear suffered a setback after Valero Energy said it was pulling out of the venture. The project had received a $20 million federal research and development grant, at least $33 million of an $80 million federal grant for construction and $20 million more from the Michigan Economic Development Corp. Midwest Energy News (8/6) | July 2013 BIO Therapeutic Newsletters The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access to our July 2013 Therapeutic Newsletters can be found here. Should you have any comments or questions, please contact Charles Crain. |  | Stop wearing your wishbone where your backbone ought to be." -- Elizabeth Gilbert, American author | | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | |
No comments:
Post a Comment